Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod

被引：4
|
作者：
Zhang, Chaoyue [1 ]
Lin, Yangtao [1 ]
Kuang, Qianjin [1 ]
Li, Hongjin [1 ]
Jiang, Qilong [1 ]
Yang, Xiaojun [1 ]
机构：
[1] Guangzhou Univ Chinese Med, Affiliated Hosp Chinese Med 1, Guangzhou, Peoples R China
来源：
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词：
myasthenia gravis; telitacicept; efgartigimod; highly active; refractory; case report; BELIMUMAB; ANTIBODY; EFFICACY; SAFETY; BAFF;
D O I：
10.3389/fimmu.2024.1400459
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
There is always a lack of effective treatment for highly active refractory generalized myasthenia gravis (GMG). Recently, telitacicept combined with efgartigimod significantly reduces circulating B cells, plasma cells, and immunoglobulin G, which brings promising therapeutic strategies. We report a case of a 37-year-old female patient with refractory GMG, whose condition got significant improvement and control with this latest treatment after multiple unsuccessful therapies of immunosuppressants. The new combination deserves further attention in the therapeutic application of myasthenia gravis.
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Efgartigimod in refractory autoimmune myasthenia gravis
    Remijn-Nelissen, Linda
    Tannemaat, Martijn R.
    Ruiter, Annabel M.
    Campman, Yvonne J. M.
    Verschuuren, Jan J. G. M.
    MUSCLE & NERVE, 2024, 70 (03) : 325 - 332
  • [2] Efgartigimod is a new option for the treatment of thymoma associated myasthenia gravis: A case report
    Wang, Shuai
    Wang, Qin
    Jin, Lirong
    Ding, Jianyong
    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2024, 115
  • [3] Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report
    Zhouao Zhang
    Zhouyi Wang
    Xue Du
    Xiaoyu Huang
    Yong Zhang
    Journal of Neurology, 2024, 271 : 584 - 588
  • [4] Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report
    Zhang, Zhouao
    Wang, Zhouyi
    Du, Xue
    Huang, Xiaoyu
    Zhang, Yong
    JOURNAL OF NEUROLOGY, 2024, 271 (01) : 584 - 588
  • [5] Case Report: Telitacicept in severe myasthenia gravis: a case study with multiple autoantibodies
    Guo, Qian
    Huang, Yusen
    Wang, Fangruyue
    Fang, Le
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [6] Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report
    Ohnari, Kana
    Hashimoto, Tomoyo
    Iwanaka, Yukio
    Ohnari, Keiko
    Adachi, Hiroaki
    Okada, Kazumasa
    JOURNAL OF NEUROLOGY, 2024, 271 (05) : 2902 - 2905
  • [7] Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report
    Kana Ohnari
    Tomoyo Hashimoto
    Yukio Iwanaka
    Keiko Ohnari
    Hiroaki Adachi
    Kazumasa Okada
    Journal of Neurology, 2024, 271 : 2902 - 2905
  • [8] Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study
    Lin, Jing
    Li, Yue
    Gui, Mengcui
    Bu, Bitao
    Li, Zhijun
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [9] Use of Efgartigimod in Treatment of Myasthenia Gravis Relapse after Possible Recurrence of Invasive Thymoma: A Case Report
    Akemokwe, Fatai
    Coskun, Elif
    Meyerson, Shari
    Ebong, Ima
    NEUROLOGY, 2023, 100 (17)
  • [10] Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis
    Sivadasan, Ajith
    Bril, Vera
    IMMUNOTHERAPY, 2023, 15 (08) : 553 - 563
12345